
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
Our innovative excipients and coatings, along with our formulation expertise and biopharma services, provide our customers with a complete portfolio of solutions for the development and manufacture of solid and liquid dosage forms.
S
tability, reliability, security-that’s our promise. We embrace the needs of our customers across all segments of the health-science industry worldwide. Our innovative excipients and coatings, along with our formulation expertise and biopharma services, provide our customers with a complete portfolio of solutions for the development and manufacture of solid and liquid dosage forms. That´s how we bring health science to life.
CPhI North America Booth Number: 843






